ABBV vs ALMS
ABBV: A diversified global biopharmaceutical leader with a strong footprint in immunology, neuroscience, and aesthetics, supported by a pipeline expanding into obesity. ALMS: Alumis is a clinical-stage biopharmaceutical company developing targeted TYK2 inhibitors to transform the treatment of immune-mediated and neurodegenerative diseases.
Side-by-side fundamentals
| Metric | ABBV | ALMS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $272.42 | $6.97 | |
| Market cap | $481.4B | $3.1B | |
| P/E as of 2026-10-08 | 76.54 | n/a | |
| Net margin FY2025, SEC XBRL | +6.9% | -1011.7% | ABBV higher |
| Operating margin FY2025, SEC XBRL | +24.6% | -1886.9% | ABBV higher |
| ROE FY2025, SEC XBRL | n/a | -80.8% | |
| ROA FY2025, SEC XBRL | +3.2% | -59.1% | ABBV higher |
| Debt / equity as of 2026-09-03 | 49.22 | 0.00 | ALMS lower |
| Revenue growth (YoY) as of 2026-09-03 | +10.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.8% | n/a | |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 9 | 0 | ABBV higher |
| Beta as of 2026-09-03 | 0.27 | 0.86 | |
| 1-year return as of 2026-10-08 close | +17.8% | +57.3% | ALMS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.